LSL PHARMA GROUP SECURES NEW STERI-MED COMMERCIAL AGREEMENTS EXPECTED TO GENERATE OVER $4 MILLION IN RECURRING ANNUAL REVENUES AND APPOINTS ALAIN R. DUGAL AS NEW EVP & COO

BOUCHERVILLE, QC, May 28, 2026 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) (the "Corporation" or "LSL Pharma "), a Canadian integrated pharmaceutical company, is pleased to announce the signing of a multi-year supply agreement for the distribution of Erythromycin manufactured by its subsidiary Steri-Med Pharma Inc. ("Steri-Med") to hospitals located outside the Province of Québec. In addition, Sterisporin^TM, our over-the-counter ophthalmic ointment product, also manufactured by Steri-Med, has recently been listed by the two largest Canadian pharmacy chains outside Québec, significantly expanding the product's national retail presence. These new commercial agreements and retail listings are expected to generate more than $4 million in additional recurring annual revenues for the Corporation.